Comparative Pharmacology
Head-to-head clinical analysis: MIVACURIUM CHLORIDE versus ROCURONIUM BROMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MIVACURIUM CHLORIDE versus ROCURONIUM BROMIDE.
MIVACURIUM CHLORIDE vs ROCURONIUM BROMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mivacurium chloride is a non-depolarizing neuromuscular blocking agent that competitively binds to nicotinic acetylcholine receptors at the motor end-plate, preventing acetylcholine from binding and thereby inhibiting neuromuscular transmission. It is a mixture of stereoisomers and is rapidly hydrolyzed by plasma cholinesterase.
Competitive antagonist at nicotinic acetylcholine receptors at the neuromuscular junction, blocking acetylcholine binding and inhibiting muscle contraction.
0.15-0.25 mg/kg IV bolus for endotracheal intubation; maintenance infusion: 0.5-1.5 mcg/kg/min IV
0.6 mg/kg IV bolus for intubation; maintenance: 0.1-0.2 mg/kg IV bolus as needed or continuous infusion 5-10 mcg/kg/min.
None Documented
None Documented
Terminal elimination half-life is approximately 2 minutes (range 1-3 minutes) for the initial rapid distribution phase, and the elimination half-life is about 17-20 minutes in patients with normal renal function. Clinically, this short half-life allows for rapid recovery of neuromuscular function.
Terminal elimination half-life: 1.4-2.4 minutes (distribution half-life: 3-5 minutes); recovery index (25-75%): 12-16 minutes; clinical duration (dose-dependent): 30-45 minutes (0.6 mg/kg) to 70-90 minutes (1.2 mg/kg)
Primarily renal excretion of unchanged drug and metabolites; approximately 90-95% eliminated via urine, with less than 5% in feces. Minor biliary excretion.
Renal: 33% unchanged; Biliary/fecal: 33% (as parent and metabolite); Hepatic metabolism: ~10-20%; remainder: unknown
Category C
Category C
Neuromuscular Blocker
Neuromuscular Blocker